文献速递甲状腺疾病

新型未分化甲状腺癌PDX与细胞系:扩展遗传多样性临床前模型

Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究从术前诊断为未分化甲状腺癌(ATC)患者的新鲜肿瘤组织同步建立PDX模型和细胞系,成功建立6个PDX模型和4个细胞系,各具不同基因突变谱。PDX模型在组织形态和免疫组化标志物上与原始患者标本高度一致,PDX建立成功率为32%,为临床前治疗试验提供工具。

要点

  • 成功建立6个ATC PDX模型和4个匹配细胞系,各具不同遗传谱。
  • PDX模型与原始肿瘤在H&E形态和免疫组化标志物上高度一致。
  • PDX建立成功率为32%,模型可用于临床前治疗试验。

核心结论

  • 成功开发并表征6个新型ATC PDX模型及4个匹配细胞系,各具不同遗传谱,为临床前治疗试验提供优秀工具。

研究设计与样本

  • 从术前诊断为ATC患者的新鲜甲状腺肿瘤手术标本同步建立细胞系和PDX模型。
  • 细胞系通过酶消化生成单细胞建立;PDX模型通过将新鲜肿瘤直接皮下植入免疫缺陷/无胸腺小鼠侧腹建立。

主要发现

  • 建立6个ATC PDX模型和4个细胞系,具有不同遗传谱。
  • 突变特征显示:1个BRAF/TP53/CDKN2A,1个BRAF/CDKN2A,1个BRAF/TP53,1个仅TP53,1个TERT启动子/HRAS,1个TERT启动子/KRAS/TP53/NF2/NFE2L2突变表型。
  • H&E染色显示PDX模型与原始患者手术标本高度相似,免疫组化标志物(细胞角蛋白、TTF-1、PAX8、BRAF)完全一致。
  • 所有PDX模型和细胞系的短串联重复DNA指纹分析与原始肿瘤高度一致。
  • PDX建立成功率为32%。

临床怎么用

  • 这些PDX模型和细胞系可用于ATC的临床前治疗试验,评估药物反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Anaplastic thyroid cancer (ATC) is a rare, aggressive, and deadly disease. Robust preclinical thyroid cancer models are needed to adequately develop and study novel therapeutic agents. Patient-derived xenograft (PDX) models may resemble patient tumors by recapitulating key genetic alterations and gene expression patterns, making them excellent preclinical models for drug response evaluation. OBJECTIVE: We developed distinct ATC PDX models concurrently with cell lines and characterized them in vitro and in vivo. METHODS: Fresh thyroid tumor from patients with a preoperative diagnosis of ATC was surgically collected and divided for concurrent cell line and PDX model development. Cell lines were created by generating single cells through enzymatic digestion. PDX models were developed following direct subcutaneous implantation of fresh tumor on the flank of immune compromised/athymic mice. RESULTS: Six ATC PDX models and 4 cell lines were developed with distinct genetic profiles. Mutational characterization showed one BRAF/TP53/CDKN2A, one BRAF/CDKN2A, one BRAF/TP53, one TP53 only, one TERT-promoter/HRAS, and one TERT-promoter/KRAS/TP53/NF2/NFE2L2 mutated phenotype. Hematoxylin-eosin staining comparing the PDX models to the original patient surgical specimens show remarkable resemblance, while immunohistochemistry stains for important biomarkers were in full concordance (cytokeratin, TTF-1, PAX8, BRAF). Short tandem repeats DNA fingerprinting analysis of all PDX models and cell lines showed strong concordance with the original tumor. PDX successful establishment rate was 32%. CONCLUSION: We have developed and characterized 6 novel ATC PDX models with 4 matching cell lines. Each PDX model harbors a distinct genetic profile, making them excellent tools for preclinical therapeutic trials.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Maniakas A, Henderson YC, Hei H, et al. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity. J Clin Endocrinol Metab. 2021. PMID: 34147031. doi:10.1210/clinem/dgab453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。